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Objective. To screen the susceptibility genes in Chinese pedigrees with early-onset familial Parkinson’s disease (FPD). Methods.
Fifty-one genomic DNA samples extracted from two Chinese pedigrees with FPD, the alpha-synuclein genes (SNCA), the leucine-
rich repeat kinase 2(LRRK2), PINK1(PTEN-induced putative kinase 1), PARK7(Protein DJ1), PARK2(Parkinson juvenile disease
protein 2), the glucocerebrosidase (GBA), and ATP(Ezrin-binding protein PACE-1), were sequenced by the use of polymerase
chain reaction (PCR) technique. The gene dose of SNCA was checked. Results. There were only two missense mutations observed,
respectively, at exon 5 of LRRK2 and exon 10 of PARK2, and both were enrolled in SNPs. Conclusion. No meaningful mutations
could be detected, and other susceptibility genes should be detected in FDP patients in China.
1.Background
Parkinson’sdisease(PD)ischaracterizedbythedegeneration
ofdopaminergicneuronsinthesubstantianigrainmidbrain.
The etiology of PD is multifactorial, and PD is likely
to involve diﬀerent factors in diﬀerent genetically related
populations. Several diﬀerent genes have been identiﬁed as
susceptibility genes of familial PD(FDP) including alpha-
synuclein gene (SNCA) and the leucine-rich repeat kinase
2 (LRRK2) mutations, which underlie autosomal domi-
nant forms of PD, and mutations or multiplications of
PINK1(PTEN-induced putative kinase 1), PARK7(Protein
DJ1), and PARK2(Parkinson juvenile disease protein 2), with
a u t o s o m a lr e c e s s i v ef o r m so fP D[ 1–4], especially in Chinese
[5, 6]. Recent studies found an increased frequency of
mutations in the gene encoding glucocerebrosidase (GBA), a
deﬁciency of which causes Gaucher’s disease in patients with
Parkinson’s disease [7]. ATP(Ezrin-binding protein PACE-1)
variant is related to FPD too [8, 9]. We selected 51 genomic
DNA samples from two Chinese pedigrees with FPD to
screen the SNCA, LRRK2, PINK1, DJ1, parkin2, GBA, and
ATP genes.
2.SubjectsandMethods
We selected two Chinese pedigrees with typical FPD from
two families. Family 1 was from outpatient department of
neurology, including 4 PD patients and 17 related individu-
als, and family 2 was from a disease census survey in rural
areas, including 4 PD patients and 26 related individuals. All
PD patients were diagnosed based on UK PD Brain Bank
Clinical diagnostic criteria [10] and were followed up for
o v e r3y e a r s .
Fifty-one genomic DNA samples were from two Chinese
pedigrees with FPD. A total of 106 pairs of primers were
designed in coding region of the alpha-synuclein genes
(SNCA, chr4: 90647204-90758290), the leucine-rich repeat
kinase 2(LRRK2, chr12: 40618813-40763075), PINK1(chr1:
20959948-20978004), PARK7(DJ1: chr1: 8021752-8045565),
PARK2(chr6: 161768452-163148803), the glucocerebrosi-
dase (GBA,chr1: 155204243-155211025), and the ATP(Ezrin-
bindingproteinPACE-1,chr1:169821804-169863076).Poly-
merase chain reaction (PCR) was carried, and the PCR
products were sequenced with 3130xl genetic sequence
analyzer (Applied Biosystems). The gene dose of SNCA2 Neurology Research International
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Figure 1: (family 1).
was checked by ABI 7900HT Fast Real-Time PCR system
(Applied Biosystems) using THUNDER BIRD SYBR qPCR
Mix (TOYOBO, Japan). (Table 1)
3. Results
The characteristics of the studied Chinese pedigrees are
presented in following Figures 1 and 2.
Family 1 included 4 PD patients. A1 manifested only
rest tremors at 58 years old, followed by muscular rigidity,
and the diagnosis was made at the age of 62 years old when
postural instability appeared. The early onset of rest tremors
in B1, B4, and B8 occurred at 24 years old, followed by
postural instability, and the diagnosis was made at the age
of 27 years old when muscular rigidity appeared. Family
2 included 4 PD patients. F2, F3, and F7 manifested rest
tremors at 29 years old, followed by postural instability, and
the diagnosis was made at the age of 32 years old when
muscular rigidity appeared. G12 manifested rest tremors at
as early as 16 years old, postural instability, and muscular
rigidity, respectively, at 17 years old, and the symptoms were
very serious. All above patients were sensitive to L-dopa
and anticholinesterase medicines, but G12 sensitivity was
gradually lowered, and the therapeutic eﬀect was not good.
Only one member (H1, female, 9 years old) was detected
to have synonymous mutation at exon 5 of LRRK2 from
the two Chinese pedigrees with FPD, rs10878245, c.578 T >
C. One member (the early onset was at 17 years old) was
observed to have a missense mutation at exon 10 of PARK2,
rs1801582, c.1272 G > C (p.380 V > L). No mutation
was found by sequencing the other exons. There was no
duplication or deletion of SNCA.
4. Discussion
We have screened the susceptibility genes causing FDP
in China, but have not found any meaningful mutations.
These observations suggest that the reported mutations
are not the predominant genotype of Chinese FPD. The
mutations of patients with FPD in the mainland China
may be diﬀerent from those in Europe, America, and other
diﬀerent genetically related populations. They are of ethnic
and geographical distribution [11].
F row patients are attacked at 32 years of age, but G12
patient at as early as 17 years old, and the clinical symptoms
areseriousduetointermarriage.Byguessing,theinheritance
maps of family 2, G12 has homozygous state of causative
genes of PD. Doubling of the mutant gene may accelerate the
onset of PD.
We have investigated only 8 FPD patients, which could
not represent the entire Chinese PD. A, B, and C rows of
family 1 live in the same environment and are on similar
diet. D, E, F, G, and H rows of family 2 are the same too.
T h ea g er a n g eo fC 1t oC 1 1o ff a m i l y1i sf r o m3t o2 3
years old, and of G and H rows of family 2 are from 9
to 30 years old, who could be too young to exhibit PD
clinical symptoms except for G12 due to intermarriage. The
number of potential PD patients is probably larger than 20
cases in the two Chinese pedigrees. The genotype association
is consistent relatively because two Chinese pedigrees are
of one pedigrees’ FPD, and G12 may be in homozygous
gene state, so the positive rate of the susceptibility genes
should be high. We conclude that multifactorial and genetic
polymorphic maybe the genuine etiology of PD [1, 9], but
not dependent genotype. Perhaps, impaired mitochondrial
dynamics and function are responsibile for Chinese FPD
[12–14], or defects in repairing oxidative DNA damage can
lead to a number of neurological disorders, as Alzheimer
and Parkinson’s disease [15] .T h ea b o v eg e n e sd u p l i c a t i o no r
triplication probably induces mutations of PD [16, 17], and
we are going to do it for Chinese FPD in the next step.
5. Additional Information
UKParkinson’sDiseaseSocietyBrainBankClinicalDiagnostic
Criteria
Step 1 (diagnosis of Parkinsonian syndrome).
(i) Bradykinesia.
(ii) At least one of the following:
(a) muscular rigidity,
(b) 4–6Hz rest tremor,
(c) Postural instability not caused by primary
visual, vestibular, cerebellar, or proprioceptive
dysfunction.
Step 2 (exclusion criteria for Parkinson’s disease).
(i) History of repeated strokes with stepwise progression
of parkinsonian features.
(ii) History of repeated head injury.
(iii) History of deﬁnite encephalitis.
(iv) Oculogyric crises.
(v) Neuroleptic treatment at onset of symptoms.
(vi) More than one aﬀected relative.
(vii) Sustained remission.
(viii) Strictly unilateral features after 3 years.
(ix) Supranuclear gaze palsy.
(x) Cerebellar signs.
(xi) Early severe autonomic involvement.
(xii) Early severe dementia with disturbances of memory,
language, and praxis.
(xiii) Babinski sign.Neurology Research International 3
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Table 1
1. PCR
DW 15.1μL 14.1μL
DMSO — 1.0μL 94◦C 10min–94◦C3 0s e c ↓–72◦C 10min–4◦C
10 × PCR Buf 2.0μL 2.0μL 52◦Ct o6 0 ◦C3 0s e c ↓
2.5mM dNTP 1.0μL 1.0μL 72◦C4 5s e c ↓
3.5U/ul HiFi 0.3μL 0.3μL ×40 cycles
10pm For primer 0.5μL 0.5μL
10pm Rev primer 0.5μL 0.5μL
DNA 0.6μL 0.6μL
Total 20.0μL 20.0μL
2. Sequence
DW 6.3μL
1 × Seq Buf 1.0μL 96◦C 1min–96◦C1 0s e c ↓–4◦C
BigDye 0.2μL 60◦C4m i n ↓
0.8pm For primer (or Rev primer) 2.0μL ×30 cycles
Template DNA 0.5μL
Total 10.0μL
3. Denature 95◦C 5min–4◦C
4. QPCR
THUNDERBIRD SYBR qPCR Mix 9μL 95◦C 1min–95◦C1 5s e c
Forward Primer 6pmol 57◦C2 0s e c
Reverse Primer 6pmol 72◦C4 0s e c
50× ROX reference dye 0.36μL ×40 cycles
Template DNA 1 μL
Upto18 microlitter
(xiv) Presenceofcerebraltumororcommunicationhydro-
cephalus on imaging study.
(xv) Negative response to large doses of levodopa in
absence of malabsorption.
(xvi) MPTP exposure.
Step 3 (supportive prospective positive criteria for Parkin-
son’s disease). Three or more required for diagnosis of
deﬁnite Parkinson’s disease in combination with step one.
(i) Unilateral onset.
(ii) Rest tremor present.
(iii) Progressive disorder.
(iv) Persistent asymmetry aﬀecting side of onset most.
(v) Excellent response (70%–100%) to levodopa.
(vi) Severe levodopa-induced chorea.
(vii) Levodopa response for 5 years or more.
(viii) Clinical course of ten years or more.
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